Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma - PubMed (original) (raw)
. 1997 Oct;33(12):1911-6.
doi: 10.1016/s0959-8049(97)00284-0.
S B Bordow, P S Haber, G M Marshall, M Kavallaris, J Madafiglio, S L Cohn, H Salwen, M L Schmidt, D R Hipfner, S P Cole, R G Deeley, M Haber
Affiliations
- PMID: 9516823
- DOI: 10.1016/s0959-8049(97)00284-0
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma
M D Norris et al. Eur J Cancer. 1997 Oct.
Abstract
We have recently shown that expression of the multidrug resistance-associated protein (MRP) gene is a powerful prognostic indicator in childhood neuroblastoma and have suggested that the MYCN oncogene may regulate MRP gene expression. To address this hypothesis, we have examined the relationship between MYCN and MRP gene expression in neuroblastoma tumours and cell lines. MYCN and MRP gene expression were highly correlated in 60 primary untreated tumours both with (P = 0.01) and without MYCN gene amplification (P < 0.0001). Like MRP, high MYCN gene expression was significantly associated with reduced survival, both in the overall study population and in older children without MYCN gene amplification (relative hazards = 13.33 and 19.61, respectively). Inhibition of MYCN, through the introduction of MYCN antisense RNA constructs into human neuroblastoma cells in vitro, resulted in decreased MRP gene expression, determined both by RNA-PCR and Western analysis. The data are consistent with MYCN influencing neuroblastoma outcome by regulating MRP gene expression.
Similar articles
- The prognostic value of MDR1 gene expression in primary untreated neuroblastoma.
Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD. Haber M, et al. Eur J Cancer. 1997 Oct;33(12):2031-6. doi: 10.1016/s0959-8049(97)00229-3. Eur J Cancer. 1997. PMID: 9516848 - Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
Haber M, Bordow SB, Gilbert J, Madafiglio J, Kavallaris M, Marshall GM, Mechetner EB, Fruehauf JP, Tee L, Cohn SL, Salwen H, Schmidt ML, Norris MD. Haber M, et al. Oncogene. 1999 Apr 29;18(17):2777-82. doi: 10.1038/sj.onc.1202859. Oncogene. 1999. PMID: 10348353 - Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.
Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Norris MD, et al. N Engl J Med. 1996 Jan 25;334(4):231-8. doi: 10.1056/NEJM199601253340405. N Engl J Med. 1996. PMID: 8532000 - Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Bordow SB, et al. J Clin Oncol. 1998 Oct;16(10):3286-94. doi: 10.1200/JCO.1998.16.10.3286. J Clin Oncol. 1998. PMID: 9779703 Review. - Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD; United Kingdom Children Cancer Study Group. George RE, et al. Med Pediatr Oncol. 2001 Jan;36(1):169-76. doi: 10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U. Med Pediatr Oncol. 2001. PMID: 11464876 Review.
Cited by
- Binomial mitotic segregation of MYCN-carrying double minutes in neuroblastoma illustrates the role of randomness in oncogene amplification.
Lundberg G, Rosengren AH, Håkanson U, Stewénius H, Jin Y, Stewénius Y, Påhlman S, Gisselsson D. Lundberg G, et al. PLoS One. 2008 Aug 29;3(8):e3099. doi: 10.1371/journal.pone.0003099. PLoS One. 2008. PMID: 18769732 Free PMC article. - Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.
Garbati P, Barbieri R, Calderoni M, Baldini F, Nizzari M, Modesto P, Florio T, Pagano A. Garbati P, et al. Int J Mol Sci. 2021 Jun 23;22(13):6753. doi: 10.3390/ijms22136753. Int J Mol Sci. 2021. PMID: 34201814 Free PMC article. - Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. Chesler L, et al. Neoplasia. 2008 Nov;10(11):1268-74. doi: 10.1593/neo.08778. Neoplasia. 2008. PMID: 18953436 Free PMC article. - Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL, Chang HY, Chang JY, Hsu WM, Huang HC, Juan HF. Hsu CL, et al. Oncotarget. 2016 Jun 14;7(24):36293-36310. doi: 10.18632/oncotarget.9202. Oncotarget. 2016. PMID: 27167114 Free PMC article. - A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. Hirschmann-Jax C, et al. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33. doi: 10.1073/pnas.0400067101. Epub 2004 Sep 20. Proc Natl Acad Sci U S A. 2004. PMID: 15381773 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical